Published in Disease Risk Factor Week, November 21st, 2004
For the second fiscal quarter, Abaxis reported record revenues of $13.6 million, compared with revenues of $11.5 million for the comparable period last year, an increase of 18%.
Recurring reagent disc and hematology reagent revenue increased by $2.1 million or 31% over the same period last year. The company reported net income attributable to common shareholders of $1.3 million, compared to $879,000 for the same period last year; an increase of 53%.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Disease Risk Factor Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.